metaPreg - Mebendazole during pregnancy

Mebendazole updated on 01-29-2025

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.50 [0.68, 3.27]	63%	4 studies	45,490	1,528	not evaluable	ROB	-
Major congenital malformations	1.50 [0.68, 3.27]	63%	4 studies	45,490	1,528	not evaluable	ROB	-
Digestive system anomalies	-	-	0 study					-
Genital anomalies	-	-	0 study					-
Limb defects	-	-	0 study					-
Nervous system anomalies	-	-	0 study					-
Polydactyly	13.50 [1.20, 151.44]	-	1 study	1,744	3	not evaluable	ROB	26.49 [1.70; .]
3 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Ectopic pregnancy	-	-	0 study					-
Elective/induced termination of pregnancy	8.15 [2.40, 27.73]	-	1 study	25	192	not evaluable	ROB	15.79 [4.23; .]
2 non statistically significant endpoints reported in only one study